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Purpose
The purpose of this study was to investigate the feasibility and survival benefits of combined
treatment with radiotherapy and adjuvant temozolomide (TMZ) in a Korean sample. 
Materials and Methods
A total of 750 Korean patients with histologically confirmed glioblastoma multiforme, who
received concurrent chemoradiotherapy with TMZ (CCRT) and adjuvant TMZ from January
2006 until June 2011, were analyzed retrospectively. 
Results
After the first operation, a gross total resection (GTR), subtotal resection (STR), partial 
resection (PR), biopsy alone were achieved in 388 (51.7%), 159 (21.2%), 96 (12.8%), and
107 (14.3%) patients, respectively. The methylation status of O6-methylguanine-DNA methyl-
transferase (MGMT) was reviewed retrospectively in 217 patients. The median follow-up
period was 16.3 months and the median overall survival (OS) was 17.5 months. The actu-
arial survival rates at the 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, respectively.
The median progression-free survival (PFS) was 10.1 months, and the actuarial PFS at 1-,
3-, and 5-year PFS were 42.2%, 13.0%, and 7.8%, respectively. The patients who received
GTR showed a significantly longer OS and PFS than those who received STR, PR, or biopsy
alone, regardless of the methylation status of the MGMT promoter. Patients with a methy-
lated MGMT promoter also showed a significantly longer OS and PFS than those with an
unmethylated MGMT promoter. Patients who received more than six cycles of adjuvant TMZ
had a longer OS and PFS than those who received six or fewer cycles. Hematologic toxicity
of grade 3 or 4 was observed in 8.4% of patients during the CCRT period and in 10.2%
during the adjuvant TMZ period.   
Conclusion
Patients treated with CCRT followed by adjuvant TMZ had more favorable survival rates and
tolerable toxicity than those who did not undergo this treatment.
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Introduction
Glioblastoma multiforme (GBM) is the most common 
malignant type of primary brain tumor, comprising approx-
imately 52% of all primary brain tumors [1]. Despite the use
of a multidisciplinary treatment approach, the prognosis of
GBM is extremely poor; most patients die within 2 years after
the initial diagnosis [2-4]. Currently, the standard treatment
for newly diagnosed GBM consists of a surgical resection to
the extent feasible, followed by concurrent chemoradiother-
apy with temozolomide (CCRT) and adjuvant temozolomide
(TMZ). In 2004, a randomized phase III multicenter trial 
reported that CCRT followed by adjuvant TMZ improved
the median survival and 2-year survival over postoperative
radiotherapy (RT) alone [5]. Based on these results, the U.S.
Food and Drug Administration approved the concomitant
use of TMZ with RT for newly diagnosed GBM patients.
Through a follow-up study longer than 5 years, Stupp et al.
[6] reported that CCRT followed by adjuvant TMZ improved
the long-term survival compared to RT alone, and that
methylation of the O6-methylguanine-DNA methyltrans-
ferase (MGMT) promoter was correlated with a better overall
survival (OS). Recently, Yang et al. [7] reported a variance in
the correlations between MGMT promoter methylation and
both the OS and progression-free survival (PFS) among an
ethnically-diverse sample of GBM patients. In their meta-
analysis, they found that subjects of European descent had a
better OS and PFS in GBM with the MGMT promoter methy-
lation compared to different race according to univariate or
multivariate analysis, whereas subjects of East Asian descent
had a longer OS compared to difference race according to
multivariate analysis only. Only a few studies of OS and PFS
among Korean GBM patients that account for MGMT pro-
moter methylation have been reported. In particular, there
are no large case studies of Korean GBM patients examining
the efficacy and safety of CCRT followed by adjuvant TMZ. 
This study assessed the efficacy and safety of CCRT fol-
lowed by adjuvant TMZ for patients with a newly diagnosed
GBM through a multicenter, retrospective study of a large
case series for the first time in Korea. 
Materials and Methods
1. Patient sample 
Patients older than 20 years with a newly diagnosed GBM
were assessed through retrospective chart reviews. All 
patients were confirmed histologically with GBM. Nineteen 
institutions participated in the study, and chart reviews for
the clinical and radiological findings were performed inde-
pendently and analyzed at each institution. The institutional
review boards of all participating centers approved the
study. A central pathologic review of histopathological spec-
imens from all patients included in the study was performed
by three neuropathologists (K.-H.L., Y.-S.L., and S.H.K.).
2. Treatment protocols 
All patients were treated with CCRT with or without 
adjuvant TMZ according to Stupp’s regimens [5]. The maxi-
mal surgical resection of tumors was performed within the
feasible limits. The extent of the resection was classified as a
gross total resection (GTR), subtotal resection (STR), partial
resection (PR), or biopsy alone. Patients received CCRT
within 6 weeks after the pathological confirmation of GBM
where possible. The patients were irradiated with a total
dose of 60 Gy, with daily fractions of 2 Gy given 5 days per
week for 6 weeks, using conventional three-dimensional
conformal RT. Alternative RT protocols, such as two-dimen-
sional RT and intensity-modulated RT with or without a 
simultaneous-integrated boost were included to avoid any
selection bias and reflect regular clinical situations. TMZ was
administered at 75 mg/m2 every day for 6 weeks during the
RT period. After a 4-week break, the patients received adju-
vant TMZ for the first 5 days of each 28-day cycle provided
that they continued to tolerate the treatment. The dose of 
adjuvant TMZ was 150 mg/m2/day for the first cycle, which
was increased to 200 mg/m2/day at the beginning of the sec-
ond cycle if no hematologic toxicity had occurred. 
3. Follow-up and evaluations
The extent of the resection was evaluated by postoperative
brain magnetic resonance imaging (MRI) with gadolinium
enhancement within 48 hours after surgery. The GTR was
defined as > 99% removal of the initial tumor, STR as 50%-
99%, and the PR as < 50%. The MRI scans were performed
before the first cycle and after every two or three cycles of
adjuvant TMZ. The assessments of the radiologic outcomes
were defined according to the RANO criteria [8]. The pri-
mary end-point was the OS, and the secondary end-points
were PFS and safety. The PFS was defined as the time from
the date of the initial operation to documented disease pro-
gression or the date of the final follow-up visit. The OS time
was measured from the date of the initial operation to death
or the date of the final follow-up visit. Patients who were
alive at the time of analysis were included as censored 
observations. The methylation status of the MGMT promoter
was evaluated using a methylation-specific polymerase chain
reaction where possible. The toxic effects of the treatment
194 CANCER  RESEARCH  AND  TREATMENT
were graded as follows according to the National Cancer 
Institute Common Terminology Criteria for Adverse Events
(NCI CTCAE) ver. 4.0.3: a score of 1, indicating mild adverse 
effects; 2, indicating moderate adverse effects; 3, indicating
severe adverse effects; 4, indicating life-threatening adverse
effects; and 5, denoting death related to adverse effects.
4. Statistical analysis
The prognostic factors associated with survival, including
the age at diagnosis, sex, preoperative Karnofsky perform-
ance status (KPS), tumor location, extent of resection, use of
adjuvant TMZ, and methylation status of the MGMT pro-
moter, were examined by univariate and multivariate analy-
ses. The OS and PFS were analyzed using the Kaplan-Meier
method with two-sided log-rank tests. Differences were con-
sidered statistically significant at p-value < 0.05. All statistical
analyses were performed using SPSS ver. 23.0 (IBM Corp.,
Armonk, NY).
Results
1. Patient characteristics
A total of 750 patients from 19 institutions were enrolled
and treated according to Stupp’s protocol from January 2006
until June 2011. Of these patients, 415 (55.3%) were male and
335 (44.7%) were female; the median age at the first operation
was 57.5 years (range, 20 to 86 years). Three hundred eighty-
seven patients (51.7%) showed a KPS score  90 at diagnosis.
Supratentorial lesions were observed in 719 patients (95.9%)
and infratentorial lesions were noted in 31 patients (4.1%).
Among the supratentorial lesions, deep-seated GBMs were
found in 106 patients (4.7%) and superficial GBMs were
found in 613 patients (85.3%). At the first operation, GTR,
STR, PR, and biopsy alone were achieved in 388 (51.7%), 159
(21.2%), 96 (12.8%), and 107 (14.3%) patients, respectively. A
central pathological review confirmed the diagnosis of GBM
in all cases reviewed. The median time from diagnosis to the
start of RT was 3.6 weeks (range, 0.7 to 26.6 weeks). The 
median therapeutic radiation dose was 60 Gy (range, 4 to 84
Gy). Among the 750 patients assigned to receive CCRT, 659
(87.9%) completed CCRT as planned. After CCRT, 660 
patients (88%) started adjuvant TMZ and received a median
of six cycles (range, 0 to 15 cycles); 407 patients (61.7%) com-
pleted six cycles. The reasons for not starting or not complet-
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Fig. 1. Kaplan-Meier curves showing overall survival (OS) (A) and progression-free survival (PFS) (B) according to the extent
of the resection. Patients who received gross total resection (GTR) showed a significantly longer OS (21.0 months vs. 15.8
months) and PFS (10.9 months vs. 9.1 months) than those who received subtotal resection (STR), partial resection (PR), or
biopsy (Bx) alone. 
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ing adjuvant TMZ therapy were disease progression (32.6%),
toxic effects (3.5%), and follow-up loss (2.3%). The median
KPS in those patients who completed and did not complete
adjuvant TMZ was 90 (range, 20 to 100) and 80 (30 to 100),
respectively. The methylation status of the MGMT promoter
was evaluated in 217 of the 750 patients (28.9%). Of the 217
patients, 89 (41.0%) had the methylated MGMT promoter,
and 128 (59.0%) had the unmethylated MGMT promoter. 
2. Survival outcome and progression
At the time of the analysis, 690 patients (92.0%) had died.
The median follow-up period was 16.3 months (range, 0.3 to
105.1 months), and the median OS was 17.5 months (95%
confidence interval [CI], 16.5 to 18.5). The actuarial survival
rates at 1-, 3-, and 5-year OS were 72.1%, 21.0%, and 9.0%, 
respectively. The median PFS was 10.1 months (95% CI, 9.3
to 10.9), and the actuarial PFS at 1-, 3-, and 5-year PFS was
42.2%, 13.0%, and 7.8%, respectively. In univariate analysis
for survival in all patients, the age at diagnosis (p < 0.001),
preoperative KPS (p < 0.001), tumor location (p < 0.001), 
extent of resection (p < 0.001), use of adjuvant TMZ (p < 0.001),
and methylation status of the MGMT promoter (p=0.012)
were correlated with survival. The age at diagnosis (p=0.003),
extent of the resection (p < 0.001), and use of adjuvant TMZ
(p < 0.001) were correlated with the survival in both univari-
ate and multivariate analyses. In addition, the methylation
status of the MGMT promoter (p=0.083) was not correlated
with survival in multivariate analysis. Patients who had 
received GTR showed a significantly longer OS (21.0 months
vs. 15.8 months, p=0.001) (Fig. 1A) and longer PFS (10.9
months vs. 9.1 months, p=0.001) (Fig. 1B) than those who had
received STR, PR, or biopsy alone in both univariate and
multivariate analyses. Patients with the methylated MGMT
promoter had a longer OS (23.9 months vs. 16.7 months,
p=0.012) (Fig. 2A) and longer PFS (13.2 months vs. 9.3
months, p=0.006) (Fig. 2B) than those with the unmethylated
MGMT promoter. When analyzing the extent of the resection
according to the methylation status of the MGMT, patients
receiving GTR showed a significantly longer OS than those
receiving STR, PR, or biopsy alone in the groups with both
the methylated (28.6 months vs. 16.7 months, p=0.001) 
(Fig. 3A) and unmethylated MGMT promoter (19.0 months
vs. 14.8 months, p=0.001) (Fig. 3C). As with OS, a signifi-
cantly higher PFS was observed in patients receiving GTR
compared to those receiving STR, PR, or biopsy alone in both
groups with the methylated (20.7 months vs. 11.1 months,
p=0.041) (Fig. 3B) and unmethylated MGMT promoter (10.6
months vs. 7.2 months, p=0.030) (Fig. 3D). The use of adju-
vant TMZ was associated with survival according to both
univariate and multivariate analyses. The OS and PFS were
compared in patients with the methylated and unmethylated
MGMT promoter, considering the degree of completeness of
adjuvant TMZ (Table 1). Patients with the methylated
Cancer Res Treat. 2017;49(1):193-203
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Fig. 2. Kaplan-Meier curves showing overall survival (OS) (A) and progression-free survival (PFS) (B) according to the O6-
methylguanine-DNA methyltransferase (MGMT) promoter methylation status. Patients with the methylated MGMT pro-
moter had a longer OS (23.9 months vs. 16.7 months) and longer PFS (13.2 months vs. 9.3 months) than those with the
unmethylated MGMT promoter.
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Fig. 3. Kaplan-Meier curves showing overall survival (OS) (A) and progression-free survival (PFS) (B) according to the extent
of the resection in patients with the methylated O6-methylguanine-DNA methyltransferase (MGMT) promoter. Kaplan-
Meier curves showing OS (C) and PFS (D) according to the extent of resection in patients with unmethylated MGMT pro-
moter. Patients receiving gross total resection (GTR) demonstrated a significantly longer OS than those receiving subtotal
resection (STR), partial resection (PR), or biopsy (Bx) alone in both groups with methylated (28.6 months vs. 16.7 months)
and unmethylated MGMT promoter (19.0 months vs. 14.8 months). For OS, patients receiving GTR demonstrated a signifi-
cantly longer PFS than those receiving STR, PR, or Bx alone in both groups with methylated (20.7 months vs. 11.1 months)
and unmethylated MGMT promoter (10.6 months vs. 7.2 months).
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MGMT promoter had a longer OS and longer PFS as the
number of adjuvant TMZ cycles approached six compared
to those who had the unmethylated MGMT promoter (Fig. 4).
3. Treatment-related hematologic toxicity
The incidence and degree of hematologic toxicity were 
analyzed separately according to the period of CCRT and 
adjuvant TMZ. A total of 115 patients (15.3%) showed grade
3 or 4 hematologic toxicity, as evaluated by CTCAE ver. 4.0.3
during the CCRT and the adjuvant TMZ period. During the
CCRT period, grade 3 or 4 hematologic toxicity was noted in
63 patients (8.4%), including 41 patients (5.5%) with lympho-
cytopenia, 10 patients (1.3%) with neutropenia, eight patients
(1.1%) with thrombocytopenia, seven patients (0.9%) with
leukopenia, and five patients (0.7%) with anemia. During the
adjuvant TMZ period, grade 3 or 4 hematologic toxicity was
reported in 66 patients (10.2%), including 42 patients (6.4%)
with lymphocytopenia, 17 patients (2.6%) with neutropenia,
13 patients (2.0%) with thrombocytopenia, five patients
(0.8%) with anemia, and two patients (0.3%) with leukope-
nia.
Discussion
In previous studies, age, performance status, extent of 
resection, methylation status of the MGMT promoter, and
the use of TMZ were identified as prognostic factors for 
patients with GBM [6,9,10]. In the present study, age, extent
of the resection, and use of adjuvant TMZ were correlated
with a better OS according to univariate and multivariate
analyses, whereas the tumor location and methylation status
of the MGMT promoter were prognostic factors of OS in uni-
variate analysis alone. These findings are consistent with
those of previous studies. Table 2 summarizes the results of
Stupp’s trial and other studies in East Asian samples.
In 2004, the European Organization for Research and
Treatment of Cancer (EORTC) and National Cancer Institute
of Canada (NCIC) trial (Stupp’s trial) demonstrated a median
OS and PFS of 14.6 and 6.9 months in patients with newly
diagnosed and histologically proven GBM, respectively. In
the present study, the median OS and PFS were 17.5 and 10.1
months, respectively. Although the treatment in the present
study was based on Stupp’s protocol, better clinical out-
comes were observed than those of Stupp’s trial. Several dif-
ferences were observed between the studies, which could
explain the improved survival. One possible explanation was
the superior GTR rate. The number of TMZ-treated patients
who received GTR was larger than that in Stupp’s trial
Cancer Res Treat. 2017;49(1):193-203
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(51.7% vs. 39%). The literature indicates that GTR is a signif-
icant prognostic factor in patients with a primary GBM 
[11-15]. In the current series, patients who received GTR
showed a longer OS and longer PFS than those who received
STR, PR, or biopsy alone, regardless of the methylation status
of the MGMT promoter. Selection bias may also have 
occurred due to the differences between a prospective ran-
domized study (Stupp’s trial) and a retrospective multi-
institutional study (the present study).
The methylation status of the MGMT promoter is a sug-
gested predictive factor of the survival of patients with newly
diagnosed GBM treated with RT and TMZ [6,16,17]. The epi-
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genetic silencing of the MGMT gene by methylation of the
MGMT promoter leads to a loss of MGMT expression and a
decrease in DNA repair activity, resulting in increased sen-
sitivity to TMZ and a longer OS [5]. On the other hand,
whether methylation of the MGMT promoter is truly a prog-
nostic marker or a predictive marker of the sensitivity to
alkylating agents or radiation is unclear [18-20]. In the cur-
rent study, the MGMT methylation status was a prognostic
factor of survival in univariate analysis alone. Patients with
a methylated MGMT promoter and underwent Stupp’s pro-
tocol showed significantly a longer OS and longer PFS than
those with the unmethylated MGMT promoter. These results
are consistent with those of a previous study [18]. Among
the 573 patients enrolled in Stupp’s trial, Hegi et al. [18] 
analyzed the MGMT methylation status in 206 patients for
whom the MGMT status could be evaluated. In 106 patients
who received CCRT, patients with methylated MGMT pro-
moter (43.4%) showed a significantly longer OS and longer
PFS than those with the unmethylated MGMT promoter
(56.6%) (OS, 21.7 months vs. 12.7 months; PFS, 10.3 months
vs. 5.3 months). These results also imply that a methylated
MGMT promoter is predictive of a response to RT and is a
prognostic factor in GBM.
The differences in survival between the present and pre-
vious studies could also be explained by the early start of
postoperative RT and the number of adjuvant TMZ cycles
administered. The median cellular doubling time of GBM is
17 days. As the tumor grows and produces satellite growths,
the chance of a regional miss increases during radiation treat-
ment [21]. Consequently, any delays in time from surgery to
the start of RT are correlated with a poor survival [22]. The
median time from surgery to the start of RT was 5 weeks in
Stupp’s trial, whereas postoperative RT was started within a
median time of 3.5 weeks in the present study. A disparity
in the degree of completion of adjuvant TMZ was observed
between the groups. Although adjuvant TMZ was adminis-
tered for a maximum of six cycles in Stupp’s trial, in the pres-
ent study, adjuvant TMZ was continued provided that it was
tolerated (median cycle, 3 cycles vs. 6 cycles, respectively).
The number of patients completing six cycles of adjuvant
TMZ was also greater in the present study than in Stupp’s
trial (61.7% vs. 47%). Seiz et al. [23] compared the OS and PFS
in patients who received six cycles or fewer and more than
six cycles of adjuvant TMZ. Among a total of 114 patients
treated with Stupp’s protocol, 55 received adjuvant TMZ of
six cycles or less, and 59 received more than six cycles. Cor-
relations were observed between the degree of completion
of adjuvant TMZ and both OS and PFS [23]. In the present
study, the administration of adjuvant TMZ after CCRT was
the strongest prognostic factor of survival, and the degree of
completion of adjuvant TMZ was correlated with the OS and
PFS regardless of the methylation status of the MGMT pro-
moter. These results suggest that adjuvant TMZ is crucial for
prolonging the OS and PFS in Korean patients with a newly
diagnosed GBM. 
Finally, the incidence of hematologic toxicity of grade 3 or
4 during the CCRT period was slightly greater in the present
study than in Stupp’s trial (8.4% vs. 6.7%). In contrast to the
CCRT period, the incidence of hematologic toxicity of grade
3 or 4 during the adjuvant TMZ period was lower in the pres-
ent study than in Stupp’s trial (10.2% vs. 14.3%). Hematologic
toxicity of grade 3 or 4 was considered tolerable compared
to other studies [5,10,24,25]. 
Conclusion
Patients treated with CCRT followed by adjuvant TMZ
had more favorable survival rates and tolerable toxicity. On
the other hand, the present study has limitations because of
its retrospective nature, the study range was restricted to
adult GBM, and the use of a different treatment protocol
from that already recognized as the standard for newly 
diagnosed GBM. Nevertheless, this study is the first large,
multicenter, observational study of GBM treatment in a sam-
ple of Korean patients. A randomized, prospective study of
a large case series will be needed explore ways of improving
the survival among Korean GBM patients. 
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